Neurocrine Biosciences Inc. reports biopharmaceutical developments across neurological, psychiatric, endocrine and immunological disorders. Recurring updates include commercial and clinical information for INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, CRENESSITY for classic congenital adrenal hyperplasia, and approved therapies for endometriosis and uterine fibroids.
Company news also covers CAHtalyst clinical data, peer-reviewed publications on glucocorticoid dosing and the Tardive Dyskinesia Impact Scale, pipeline programs such as NBIP-'2118, financial results, healthcare conference participation, and governance or capital-structure matters tied to Neurocrine's public-company reporting.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the Bank of America Securities 2020 Napa Biopharma Conference on June 22, 2020, at 2:00 p.m. PT (5:00 p.m. ET). CEO Kevin Gorman will lead the presentation. The live event will be webcast and available on the company's website, with a replay accessible one hour after the event and archived for approximately one month. Neurocrine focuses on developing treatments for neurological and endocrine disorders, with a portfolio that includes FDA-approved therapies for conditions like tardive dyskinesia and Parkinson's disease.